We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Johnson & Johnson to Buy Scios for $2.4 Billion

By Biotechdaily staff writers
Posted on 26 Feb 2003
In a transaction that will broaden its drug pipeline and provide promising research projects, Johnson & Johnson (New Brunswick, NJ, USA) has agreed to acquire Scios, Inc. More...
(Sunnyvale, CA, USA) a biopharmaceutical company, for about US$2.4 billion. Johnson & Johnson is a manufacturer of a wide range of health-care products.

Scios' Natrecor is the first new agent approved for congestive heart failure (CHF) in more than a decade. Natrecor is a recombinant form of a B-type natriuretic peptide secreted by the heart as part of the body's response to CHF and has several significant advantages over existing therapies. The principal focus of Scios' research program is small molecule inhibitors. The program includes several potential new treatments for pain and inflammation, including an advanced p-38 kinase inhibitor.

"Scios strengthens our growing cardiovascular franchise and broadens our pipeline with several potential new chemical entities,” said Christine Poon, worldwide chairman, Pharmaceuticals Group, Johnson & Johnson. "Natrecor is a truly unique product for a largely underserved and growing market. Scios also brings an advanced research program on kinase inhibitors, which is an exciting new area of research.”




Related Links:
J&J
Scios

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: An elevated neutrophil-to-lymphocyte ratio (NLR), a rato easily obtained from a routine blood count, was associated with both short- and long-term Alzheimer’s risk (photo credit: 123RF)

Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk

Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.